Refinement and Assessment of New Magnetic Resonance Imaging Technologies for Neurological Exams
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Refinement and Assessment of New Magnetic Resonance Imaging (MRI) Technologies|
- Improvement in quality of MRI studies in Neuroradiology [ Time Frame: 1 year ]
Specific Measurement Are:
- Scan speed - is the new method as fast or faster than regular method(s)
- Signal to noise - Subjectively, or quantitatively do we get the same, better, or new contrast compared to the regular methods(s).
- Image contrast - Subjectively, or quantitatively do we get the same or better resolution compared to the regular method(s).
- Spatial resolution - Subjectively, or quantitatively do we get the same or better resolution compared to the regular method(s).
- Artifact - Subjectively, or quantitatively do we get the better artifact reduction compared to the regular method(s).
- Ergonomics - Is the new software easier to work or offer more information more cleanly than the regular software
- Patient comfort - Subjectively, does the new software and/or hardware make the patient's MRI experience more comfortable.
|Study Start Date:||October 2004|
|Estimated Study Completion Date:||December 2017|
|Estimated Primary Completion Date:||January 2017 (Final data collection date for primary outcome measure)|
NEW technology MRI
Neurological MRI with new technology evaluation
This study is being done to assess new Magnetic Resonance Imaging (MRI) technologies such as new hardware or software designed to improve MRI examinations of the brain, spine, and head & neck regions.
Software and hardware are constantly being improved, new machines replace old machines, software is updated and improved as are the devices used to produce better MRI images.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00739518
|United States, Michigan|
|University of Michigan Health System|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Ashok Srivinasan, MD||University of Michigan|